Kornimate/medical-research-clean huggingface dataset:
determinants of the effectiveness of robot-assisted hand movement training

Conditions: Stroke, Ischemic; Cerebrovascular Accident (CVA)

Summary: the investigators would like to investigate the effectiveness of somatosensory training for robot-assisted hand motor rehabilitation after stroke.

from previous studies, the investigators learned that stroke survivors with impaired finger proprioception did not achieve as large a functional benefit from robotic finger training. for this study, the investigators would like to determine if and the extent of finger proprioception can be improved through targeted robotic proprioceptive training combined with robotic finger movement training. the investigators would also include imagining studies via electroencephalogram (eeg) and other baseline predictors to provide insight to determine who responds best to proprioceptive training.

Eligibility criteria:
inclusion criteria: * age 18 to 85 years * suffered from a single ischemic stroke (radiologically confirmed) at least 6-months prior to enrollment * an ability to score at least 3 blocks on the box and block test exclusion criteria: * a substantial decrease in alertness, language reception or attention * pregnant or lactating * advanced liver, kidney, cardiac or pulmonary disease * plan to alter any current participation in other rehabilitation therapy in the time period of the study * a terminal medical diagnosis consistent with survival \< 1 year * coexistent major neurological disease * coexistent major psychiatric disease * a history of significant alcohol or drug abuse in the prior 3 years * current enrollment in another study related to stroke or stroke recovery * any other medical contraindication to participation in this study evaluated by our team physician.

Keywords: rehabilitation
prospective evaluation of changes in tissue oxygen saturation in brain and kidney in children admitted to intensive care in the postoperative period of cardiac surgery

Conditions: Congenital Heart Defect

Summary: it is estimated that the incidence of congenital heart disease varies between 0.5 and 1% of live births, 5,000 new cases per year currently in france these are serious diseases that can be life-threatening to more or less short term. the advances in surgical techniques in recent years has improved the prognosis of these patients in the first months of life. the success of surgery is, among other things, conditioned by a support per complex operation, involving a multimodal intensive monitoring, and respiratory and hemodynamic support techniques. these elements of surveillance, nirs (near-infrared spectroscopy) allows measurement of non-invasive tissue saturation (rso2) in cerebral and renal oxygen. the fundamental principle of nirs based on an estimate of the percentage proportion of cerebral oxy-hemoglobin. a light source is emitted by nirs and through body tissues to the brain where the light will be absorbed and refracted depending on the tissue composition in oxy-hemoglobin. refracted light will be analyzed by nirs which in turn using software will help to determine a percentage of oxyhemoglobin. normal values of cerebral nirs are between 50 and 80%.nirs can be used according to this principle to estimate cerebral tissue oxygenation but also for other tissues such as the kidney. more than the figure, those are changes nirs compared to a baseline that will alert us to the conditions of tissue oxygenation and allow us to identify hypoxia times. changes in the value of the nirs depends on 3 criteria: the tissue blood flow, the percentage of oxyhemoglobin and deoxyhemoglobin percentage.


Eligibility criteria:
inclusion criteria * children under 5 years * allowed in pediatric intensive care unit * having received heart surgery for management of congenital heart disease exclusion criteria * patients aged over 5 years * violations preexisting brain to the intervention (brain malformation) * patients with congenital heart disease and admitted to intensive care for reasons other than the surgical treatment of heart disease

Keywords: congenital heart nirs
lapatinib resistance in patients with breast cancer

Conditions: Breast Cancer

Summary: rationale: studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about cancer and the development of drug resistance in patients. purpose: this research study is looking at lapatinib resistance in patients with breast cancer.

objectives: * to identify secondary erbb2 mutations in tumor tissue samples from patients with erbb2-positive breast cancer treated with lapatinib ditosylate. * to investigate erbb2 copy number changes and expression levels. * to determine abnormalities of other pathways (e.g., c-met and pi3k) as potential mechanisms of resistance. outline: previously collected tumor tissue samples\* are obtained for genetic analysis studies. samples are analyzed for secondary erbb2 mutations by nested pcr; erbb2 copy number changes by quantitative pcr and standard histological fish; and erbb2 expression levels by quantitative rt-pcr and ihc. patients also undergo blood sample collection for extraction of dna (as normal control dna) and isolation of epcam-positive circulating tumor cells using immunomagnetic cell separation technology. additional research studies may include mutational and amplification analysis of the c-met and pi3k pathways. note: \*patients may undergo biopsy if a post-treatment tumor tissue sample is unavailable.

Eligibility criteria:
disease characteristics: * pathologically confirmed invasive breast cancer * erbb2-positive disease * has received or is currently receiving lapatinib ditosylate * documented clinical benefit while receiving lapatinib ditosylate (e.g., stable disease of ≥ 12 weeks duration or a radiographic response) * must have tumor tissue samples available for research studies * hormone receptor status not specified patient characteristics: * menopausal status not specified * not pregnant\* * coagulation profile normal\* * platelet count \> 100,000/mm³\* note: \*for patients requiring a post-treatment biopsy prior concurrent therapy: * see disease characteristics * concurrent chemotherapy or trastuzumab (herceptin®) allowed * no concurrent anticoagulants, including warfarin or low-molecular weight heparin\* * no concurrent antiplatelet therapy, including aspirin, clopidogrel, or other antiplatelet agents\* note: \*for patients requiring a post-treatment biopsy

Keywords: breast cancer
single incision laparoscopic cholecystectomy

Conditions: Cholelithiasis

Summary: the investigators aim to investigate the safety, feasibility and short-term outcomes of single incision laparoscopic cholecystectomy. the investigators hypothesize that single incision laparoscopic cholecystectomy is safe and feasible.

laparoscopic cholecystectomy is the standard approach for the treatment of gallbladder disease. laparoscopic cholecystectomy is now performed as an outpatient procedure and it commonly requires the use of 4 separate small incisions. single incision or single access trans-umbilical surgery may provide less pain, scarring and may improve patient's overall satisfaction. in this phase i trial we aim to evaluate the safety, feasibility and short-term outcomes of single incision laparoscopic cholecystectomy for the treatment of symptomatic cholelithiasis (gallstones).

Eligibility criteria:
inclusion criteria: * adults male and female(\>18 years old) * capable of giving informed consent * ultrasound proven cholelithiasis * symptomatic cholelithiasis * elective cholecystectomy exclusion criteria: * pregnancy * contraindications for general anesthesia * morbid obesity * multiple previous abdominal surgeries * uncontrolled medical conditions * acute cholecystitis

Keywords: single incision single access surgery cholecystectomy
study of individualized physiotherapy for airway clearance in cystic fibrosis.

Conditions: Cystic Fibrosis

Summary: the purpose of this study is to investigate individual efficacy in physiotherapy for airway clearance, and to investigate user experience, i.e.utility value and preference.


Eligibility criteria:
inclusion criteria: * diagnosis: cf * age \>18 years * amount of sputum \>5 ml/60 min * wet inhalation of saline/dnase/both * informed consent exclusion criteria: * respiratory failure * hemoptysis * bacteriology (burkholderia cephacia, multi-resistent pseudomonas aeruginosa, atypical mycobacteria, mrsa). * ongoing intravenous medication * pregnancy

Keywords: adults
comparison of aerobic, resistance, and combined training in overweight/obese hypertensive adults

Conditions: Obese; Hypertension

Summary: to compare the effects of aerobic, resistance and combined training in hypertensive obese patients


Eligibility criteria:
inclusion criteria: * hypertensive with bp greater than 140/90 mmhg * overweight and obese adults with bmi (25-40) * physically inactive from past 6 months assessed with pedometer. those with step count of less than 7000 will be included * to be able to exercise (6mwt),t hose who completed the test without any symptom exclusion criteria: * any active systemic illness that restricts exercise * people doing exercise on regular basis * any cardiopulmonary , metabolic and neurological illness

Keywords: aerobic exercise resistive exercise combined aerobic and resistive exercise
[68ga]dotatate-pet/mri in hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: there is great need for new therapeutic options for patients with hepatocellular carcinoma (hcc). this proposal will assess the feasibility of a novel theranostic approach to hcc using \[68ga\]dotatate, a recently approved positron emission tomography (pet) ligand for imaging somatostatin receptor (sstr) positive tumors. in this study, we will use \[68ga\]dotatate to determine the percentage of hccs that express adequate levels of sstr for treatment with targeted radionuclide therapy (trt) using the therapeutic sstr ligand \[177lu\]dotatate. this radionuclide therapy was fda approved in january 2018 for treating neuroendocrine tumors (nets) arising from the gastrointestinal tract, but its use in hcc has not yet been explored. in the long term, we envision using \[68ga\]dotatate-pet to identify hcc patients with adequate sstr expression for trt using \[177lu\]dotatate. liver transplantation is the only curative therapy for hcc and is an option for a selected subset of hcc patients. for those who are not candidates for transplantation, locoregional therapies with limited efficacy are available such as percutaneous ablation, arterial chemoembolization, and y-90 microsphere radionuclide therapies. there are few options for patients who progress or are not candidates for these therapies. the first line systemic therapy is sorafenib, a tyrosine kinase inhibitor. sorafenib is often not well tolerated due to its side effects and there is need for additional systemic treatments. multiple tissue-based studies demonstrate sstr positivity in 20-50% of hccs.\[1-3\] however, the fraction of hccs have high enough levels of sstr for \[177lu\]dotatate therapy has not yet been assessed. this research plan is a critical prerequisite for determining the feasibility of this theranostic approach to treating hcc. if we obtain positive results, these data will be critical for designing a combined imaging and therapeutic study in hcc using dotatate.


Eligibility criteria:
inclusion criteria: * known diagnosis of hepatocellular carcinoma, either by imaging criteria or pathology on biopsy * standard of care liver mri or ct demonstrating viable hcc based on arterial contrast enhancement measuring at least 1.5 cm in largest axial dimension exclusion criteria: * history of neuroendocrine tumor or other sstr-positive tumor * interval locoregional therapy or new systemic therapy between standard of care liver mri or ct study showing viable hcc and \[68ga\]dotatate-pet/mri
cognitive-behavioral treatment for rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: to evaluate the effectiveness of cognitive-behavioral treatment for people with rheumatoid arthritis


Eligibility criteria:
inclusion criteria: * diagnosed by rheumatology consultants with ra exclusion criteria: * severe psychological difficulties * currently receiving mental health care * any medical condition that might prevent them from safely exercising (e.g. history of more severe heart, lung or cerebrovascular disease) * previously attended an education programme * had a modified health assessment questionnaire score \>2 (score range 0-3), that is severe functional problems * history of organic brain syndrome * presence of a psychotic disorder * presence of other uncontrolled medical disorders * presence of a major communication disorder, illiteracy * presence of less than an 8th grade education (due to inability to complete questionnaires) * presence of a therapeutic dosage of an antidepressant medication, or presence of another autoimmune disease/disabling condition
follow up study for treatment of parkinson's disease with deep brain stimulation

Conditions: Parkinson Disease

Summary: follow up of patients enrolled in csp 468, a study of deep brain stimulation treatment for parkinson's disease

parkinson's disease (pd), the second most prevalent neurodegenerative disease (after alzheimer's disease), affects more than a million americans and is a common condition in the veteran population. although there is currently no cure for the disease, many of the symptoms of the disease can be effectively managed with medications and with deep brain stimulation (dbs). this study seeks to build upon the original csp#468 protocol by providing an efficient long-term follow-up study. the objectives of this study are to: determine whether the motor benefits of deep brain stimulation persist beyond two years of follow-up in patients with parkinson's disease; determine whether the target of stimulation (gpi vs. stn) affects the durability of long-term motor improvement; define the impact of dbs on long-term function and quality of life in patients with parkinson's disease; identify clinical features that predict favorable or unfavorable long-term outcome; and describe the long-term performance of the dbs devices, including device durability, device explanation rate, neurostimulator replacement frequency, and changes in stimulation parameters to achieve optimum symptom control.

Eligibility criteria:
inclusion criteria: * participant in csp#468 * available and willing to be followed-up according to study protocol exclusion criteria: * dbs device explanted or permanently turned off without anticipated resumption of dbs therapy.

Keywords: deep brain stimulation subthalamic nucleus globus pallidus parkinson disease
study of wa-ng (ng-imt) telescope prosthesis in patients with end-stage age-related macular degeneration

Conditions: Age Related Macular Degeneration

Summary: the purpose of this study is to evaluate the safety of the updated model wa-ng telescope prosthesis (hereafter wa-ng telescope), an injectable telescope device, in patients with bilateral moderate to profound central vision impairment due to end-stage age-related macular degeneration.

patients will be screened for eligibility and informed consent will be obtained from those who meet screening criteria and are interested in participating in the study. eligible patients will be examined preoperatively to obtain a medical history and to establish a baseline for ocular condition. postoperatively, patients will undergo ophthalmic evaluation at regular intervals as specified in this protocol.

Eligibility criteria:
\*\*the following inc. \& exc. are sample and not completed list \*\* main exclusion criteria: * patients with bilateral, stable, moderate to profound central vision impairment due to bilateral central scotoma associated with end-stage macular degeneration, defined as retinal findings of bilateral, geographic atrophy or disciform scar with foveal involvement. * patients must have distance bcva between 20/80 and 20/800, and adequate peripheral vision in one eye (the non-implanted eye) to allow navigation * patients must achieve at least a five letter improvement on the etdrs chart in the eye scheduled for surgery, with the external telescope simulator (ets) * patients must be available for the study duration of 12 months * patients must be alert, mentally competent, and able to understand and comply with the requirements of the clinical trial, and be personally motivated to abide by the requirements and restrictions of the clinical trial. main exclusion criteria: * evidence of active cnv on fluorescein angiography or treatment for cnv within the past six months. * patients who may require fellow eye cataract extraction and intraocular lens implantation during the 12 months following wa-ng telescope implantation. if fellow eye cataract extraction is anticipated, this procedure should be performed at least 30 days prior to enrollment in the clinical study. * patients who have had or are expected to have ophthalmic related surgery within the 30 days preceding implantation of the device. * patients who have undergone previous intraocular or corneal surgery of any kind in the operative eye(s), including any type of surgery for either refractive or therapeutic purposes. * patients participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation

Keywords: macular degeneration visual impairment implantable telescope
assessment of methotreaxate-induced liver fibrosis by transient elastography and serological markers

Conditions: Liver Fibrosis

Summary: methotrexate (mtx), a folic acid analogue, inhibits the synthesis of purines and pyrimidines and is widely used in the treatment of chronic inflammatory diseases, particularly rheumatoid arthritis (ra). it is typically the first-line drug for ra management. however, prolonged mtx use is associated with hepatotoxicity, including liver fibrosis (lf), which necessitates regular monitoring, especially of liver function tests mtx-induced liver injury has been recognized since the early 1970and numerous studies have shown an increased risk of liver fibrosis, which is estimated to occur in approximately 5% of patients, with a potential relationship to the cumulative dose of mtx despite intensive monitoring strategies and the recommendation for liver biopsies, liver biopsy carry significant risk, including bleeding and sampling variability . the aim of the study to estimate the frequency and stage of liver fibrosis in patients with rheumatological or dermatological diseases receiving methotrexate in assuit university hospitals in comparison to a control group with the same diseases not receiving methotrexate. evaluate the diagnostic performance of fib-4 , apri and fib-5 scores as non invasive fibrosis markers in comparison to transient elastography in these patients. identify the predictors of liver fibrosis in these patients. as such, there is increasing interest in non-invasive methods for monitoring liver fibrosis, such as liver stiffness measurement by fibroscan (fs), apri score , fib-4 score and fib-5 score . these methods offer advantages over liver biopsy, including being non-invasive, rapid, reproducible, and able to assess disease progression over time. however, the prevalence of hepatic fibrosis in mtx-treated patients, particularly in egypt, remains under-researched.


Eligibility criteria:
inclusion criteria: * adults (18 years and older) prescribed methotrexate therapy for rheumatological disease (such as systemic lupus erythematosus , rheumatoid arthritis and ankylosing spondylitis)or dermatological diseases (such as psoriasis and behcets disease). exclusion criteria: * patients with metabolic associated fatty liver disease (mafld). patients with chronic liver diseases (hbv, hcv, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic liver disease). history of chronic heart failure or renal failure.c.
first clinical live-donor uterus transplantation trial in egypt

Conditions: Primary Uterine Infertility

Summary: more than a decade ago, uterus transplantation (utx) as a highly experimental procedure was the treatment which had been developed for women suffering from absolute uterine factor infertility (aufi) \[uterus absence (congenital and surgical), or an abnormality (anatomic and functional)\]. in egypt, people's religions, current ethical and legal backgrounds make the option of live-donor uterus transplantation appealing rather than alternative pathways to parenthood. thus, its clinical application for the first time in egypt should be initiated after an extensive review and analysis of literature for utx technology development in the world, and for further possible contributions to future prospects by egypt proposed utx project team which will participate in our study.

more than a decade ago, uterus transplantation (utx) as a highly experimental procedure was the treatment which had been developed for women suffering from absolute uterine factor infertility (aufi) \[uterus absence (congenital and surgical), or an abnormality (anatomic and functional)\]. in egypt, people's religions, current ethical and legal backgrounds make the option of live-donor uterus transplantation appealing rather than alternative pathways to parenthood. thus, its clinical application for the first time in egypt should be initiated after an extensive review and analysis of literature for utx technology development in the world, and for further possible contributions to future prospects by egypt proposed utx project team which will participate in our study. the study protocol includes live-donor utx (mother, relative, friend) into women with aufi. the recipient will be treated by standard immunosuppression and transfer of embryos (acquired by ivf before surgery) will be attempted after 8-12 months have passed from transplantation. two official approvals must be obtained before starting recruitment process; from both (higher committee of human organ transplantation of egyptian ministry of health and population, and al-azhar university council).

Eligibility criteria:
inclusion criteria: * less than 45 years old * good general health exclusion criteria: * older than 45 years old * poor ovarian reserve * systematic or psychiatric disease

Keywords: uterus transplantation infertility
the moca i study - microvascular obstruction with cofi™ system assessment

Conditions: STEMI - ST Elevation Myocardial Infarction; Microvascular Obstruction

Summary: first-in-human study to assess the cofi™ device related safety and the feasibility of the diagnostic and the therapeutic sequence as well as the correlation between the dynamic microvascular resistance (dmvr) and microvascular obstruction (mvo) as measured by mri in patients presenting with acute st-elevation myocardial infarction (stemi) undergoing percutaneous coronary intervention (pci).


Eligibility criteria:
major inclusion criteria: * patients 18 years of age or older presenting with st-elevation myocardial infarction in the left anterior descending artery (lad) undergoing primary percutaneous coronary intervention. * competent mental condition to provide signed and dated ethics committee approved study consent prior to study related procedures * eligible for prasugrel, ticagrelor, cangrelor, tirofiban, ufh and gp iib/iiia inhibitors * referred for primary pci within 5 hours of symptom onset with evidence of continuing ischemia and symptom to balloon time not exceeding 6 hours major exclusion criteria: * unconsciousness * previous bypass graft surgery * contraindication to cmri * recent or current major bleeding within 30 days prior to intervention * recent major surgery within 30 days prior to intervention * end-stage heart failure with inotrope support and/or consideration for lvad or heart transplant * transient ischemic attack or stroke within 30 days prior to intervention * pregnant or females of childbearing potential